PC
TVRD

PA Capital’s Tvardi Therapeutics TVRD Stock Holding History

PA Capital’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$156K Buy
+341
New +$198K 0.11% 164

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PA Capital's TVRD Position: Q3 2020 in Review

PA Capital opened a new position in Tvardi Therapeutics (TVRD) in Q3 2020: 341 shares worth $156K. The stake represents 0.11% of the portfolio and ranks #164 among its holdings.

160 funds tracked by Wall St. Rank hold TVRD as of Q3 2020.

  • PA Capital held 341 shares of Tvardi Therapeutics worth $156K as of Q3 2020.
  • Tvardi Therapeutics was a new PA Capital position in Q3 2020.
  • Tvardi Therapeutics made up 0.11% of PA Capital's portfolio in Q3 2020, its #164 holding.
  • 160 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2020.

Based on PA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.